AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04880850
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
Trial: NCT04880850
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
Trial: NCT04880850
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
Trial: NCT05425719
Drug: MB-102
RxNorm normalized name: MB-102 CD123 CAR
DrugBank: MB-102 CD123 CAR (DB17366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
Trial: NCT00002017
Drug: Interleukin-2, Polyethylene Glycolated
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06300346
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron
Trial: NCT04962503
Drug: Afamelanotide
RxNorm normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
Trial: NCT05530278
Drug: Galicaftor
RxNorm normalized name: Galicaftor
DrugBank: Galicaftor (DB14894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05530278
Drug: ABBV-576
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05530278
Drug: Navocaftor
RxNorm normalized name: Navocaftor
DrugBank: Navocaftor (DB19039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05530278
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT05624918
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Trial: NCT05624918
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
Trial: NCT04591210
Drug: Angiotensin II Receptor Blockers
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
Trial: NCT06528015
Drug: probiotics combined with enteric-coated budesonide capsule
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Trial: NCT06528015
Drug: probiotics placebo combined with enteric-coated budesonide capsules
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Trial: NCT05956587
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05956587
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05381558
Drug: Triamcinolone Injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local injection in sinus tarsi
Trial: NCT05720273
Drug: palicalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
Trial: NCT05273658
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will smoke a cannabis cigarette ad libitum as per their usual routine
Trial: NCT05273658
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will ingest alcohol to achieve the target breath alcohol level
Trial: NCT05911464
Drug: HS-10386
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
Trial: NCT05108688
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg tablet once daily for 3 successive days
Trial: NCT05108688
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg tablet once daily for 3 successive days
Trial: NCT05603754
Drug: Lorecivivint
RxNorm normalized name: Lorecivivint
DrugBank: Lorecivivint (DB14883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
Trial: NCT06499727
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Trial: NCT05902429
Drug: Cladribine 10 mg oral tablet
RxNorm normalized name: cladribine 10 MG Oral Tablet
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
Trial: NCT05399550
Drug: Balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Solution
Trial: NCT05380349
Drug: combinations of up to 3 FDA approved drugs from a panel of compounds
RxNorm normalized name: Compound W brand of salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: personalized drug combinations
Trial: NCT06076200
Drug: Piperacillin Sodium and Tazobactam Sodium for Injection
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
Trial: NCT04334915
Drug: Cenicriviroc Mesylate (CVC)
RxNorm normalized name: mesylate
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06334172
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin
Trial: NCT05161637
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 75mg
Trial: NCT05161637
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150mg
Trial: NCT06051851
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab 200mg IV D1~1 cycle every 21 days
Trial: NCT06051851
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days
Trial: NCT06051851
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days
Trial: NCT06051851
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days
Trial: NCT05344625
Drug: Ketamine 100 MG/ML
RxNorm normalized name: ketamine 100 MG/ML
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine Assisted Psychotherapy
Trial: NCT05052541
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution containing 5mg THC per 1 ml
Trial: NCT05708924
Drug: FT538
RxNorm normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
Trial: NCT04526119
Drug: Acotiamide hydrochloride hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Acotiamide (DB12482)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
Trial: NCT06114004
Drug: Selinexor 20 MG
RxNorm normalized name: selinexor 20 MG
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
Trial: NCT06114004
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
Trial: NCT00719225
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
Trial: NCT05704439
Drug: Neurologist Initiated Treatment
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
Trial: NCT05010525
Drug: ATG-016
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle
Trial: NCT05833971
Drug: cadonilimab+chemotherapy
RxNorm normalized name: menthol
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cadonilimab plus cisplatin and Nab-PTX, Q3W
Trial: NCT06098196
Drug: Aminophyllin
RxNorm normalized name: Aminophyllin
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
Trial: NCT06329999
Drug: CMGV
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses.
Trial: NCT05624138
Drug: Ketotifen Oral Tablet
RxNorm normalized name: ketotifen Oral Tablet
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
Trial: NCT05566288
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets
Trial: NCT06165380
Drug: Cardenilimab Combined With Chemotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cardenilimab Combined With Chemotherapy
Trial: NCT04801797
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04801797
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04801797
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04801797
Drug: Liposomal daunorubicin and cytarabine
RxNorm normalized name: cytarabine liposome / daunorubicin liposomal Injection
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04801797
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally by mouth
Trial: NCT04801797
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06028425
Drug: LOXO-783
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05535309
Drug: cefoperazone sulbactam sodium
RxNorm normalized name: Cefoperazone Sodium
DrugBank: Cefoperazone (DB01329)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
Trial: NCT04578015
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
Trial: NCT05066633
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
Trial: NCT06000956
Drug: a simulated agent of Jitongning tablets
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
Trial: NCT05774704
Drug: Low curcumin group
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
Trial: NCT05774704
Drug: High curcumin group
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
Trial: NCT05905757
Drug: Tramadol + Bupivacaine
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
Trial: NCT04705337
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Trial: NCT05597917
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Trial: NCT00148421
Drug: Darbepoetin alfa and Epoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06066957
Drug: Letermovir 480 MG [Prevymis]
RxNorm normalized name: letermovir 480 MG [Prevymis]
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up.
Trial: NCT05285033
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
Trial: NCT04945824
Drug: Dexamethasone Ophthalmic
RxNorm normalized name: dexAMETHasone ophthalmic
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
Trial: NCT03089658
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
Trial: NCT05912712
Drug: Mesalazine Suppository Treatment
RxNorm normalized name: mesalamine Rectal Suppository
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
Trial: NCT05137886
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.